
United States · Medical devices startup
CytoSPAR specializes in using the power of advanced science to transform disease management with simplified diagnostic solutions.
Funding reportedLast round: Undisclosed round
CytoSPAR specializes in using the power of advanced science to transform disease management with simplified diagnostic solutions.
A flagship technology, blAST, uses direct sample phenotypic antimicrobial susceptibility testing (AST) to accelerate the process of identifying effective antimicrobial agents while reducing the time-to-results from days to mere hours. This rapid turnaround is crucial in the fight against antimicrobial resistance (AMR), ensuring patients a more timely and effective treatment. Visit our website to learn how CytoSPAR is developing solutions to diagnostic dilemmas.
Funding, as reported
From the SEC filings it signed: 1 on the team.
On the board, as filediMark AllenWilliam Weisman
What they build
Known for
medical laboratory testingmicrobial response analysishealth careantibiotic resistance testinglaboratory workflow integrationresearch use only microbiologyrapid phenotypic testingmedical equipment manufacturingspeed to treatmentpatient-friendly testingnext-generation diagnosticsurinary tract infection managementinnovative microbiology platformadvanced microbiology technologyhospital & health carebacteria response to antibiotics
Built with from their website
Google WorkspaceViewport MetaHubspotMedia Temple DNSGoogle MeetMedia TempleCAPTCHAMicrosoft ExchangeMicrosoft 365 Apps & ServicesMobile Friendly
iubendaAmazon AWSMicrosoft Exchange OnlineNginxMicrosoft 365OutlookreCAPTCHAMicrosoft Email Providers
Add your raise, your deck and your story, and put CytoSPAR in front of investors. Or tell us what we have wrong.